UK markets closed

Kezar Life Sciences, Inc. (KZR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.50+0.01 (+0.09%)
As of 1:18PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close5.49
Open5.55
Bid5.48 x 1100
Ask5.52 x 1100
Day's range5.43 - 5.62
52-week range4.24 - 7.40
Volume24,526
Avg. volume278,106
Market cap264.253M
Beta (5Y monthly)0.34
PE ratio (TTM)N/A
EPS (TTM)-0.92
Earnings date03 Aug 2021 - 09 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est15.00
  • Business Wire

    Kezar Life Sciences Announces Formation of Clinical Advisory Committee

    Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the formation of its Clinical Advisory Committee.

  • Business Wire

    Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021

    Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported results from the completed Phase 1b dose escalation portion of its MISSION study, evaluating KZR-616, a first-in-class selective immunoproteasome inhibitor, in systemic lupus erythematosus (SLE) patients with and without nephritis. The data are being presented by Richard Furie, M.D., Chief of Division of Rhe

  • Business Wire

    Kezar Appoints Rheumatology Industry Expert, Micki Klearman, MD, to its Board of Directors

    Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment of Micki Klearman, M.D. to its Board of Directors.